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Statement of Translational Relevance 
A powerful, combined strategy has been developed to study the potential effect of 
genetic variants on splicing efficiency: Bioinformatic analysis followed by functional 
analyses by lymphocyte RT-PCR and/or ex vivo hybrid minigenes. We show that a 
large proportion of BRCA1/2 variants, mostly of unknown clinical significance, are 
associated with the anomalous splicing of their corresponding genes in Hereditary 
Breast/Ovarian cancer. Anomalous splicing may therefore represent a relevant 
ethiopathogenic mechanism whose study may notably increase the proportion of 
HBOC families that may benefit from Genetic Counselling and tailored prevention 
protocols. Appropriate functional splicing assays should be incorporated to the 
screening of genetic diseases such as hereditary cancer in order to discriminate 
between benign polymorphisms and pathogenic mutations. 
ABSTRACT 
Purpose:Most BRCA1/2 mutations are of unknown clinical relevance. An increasing 
amount of evidence indicates that they can be deleterious effects through the 
disruption of the splicing process. We have investigated the impact of aberrant 
splicing of BRCA1/2 on Hereditary Breast/Ovarian Cancer (HBOC).  
Experimental Design: DNA variants were analyzed with splicing prediction 
programs to select putative splicing mutations. Splicing assays of 57 genetic variants 
were performed by lymphocyte RT-PCR and/or hybrid minigenes in HeLa and non-
tumor breast epithelial cells.  
Results: Twenty-four BRCA1/2 variants of Spanish HBOC patients were 
bioinformatically preselected. Functional assays showed that twelve variants induced 
anomalous splicing patterns, six of which accounted for 58.5% of BRCA1 families. To 
further evaluate the defective splicing of BRCA1/2, we analyzed 31 BIC (The Breast 
Cancer Information Core Database) and two artificial variants that were generated by 
mutagenesis. Sixteen variants induced different degrees of aberrant splicing. 
Altogether, anomalous splicing was caused by 28 BRCA1/2 variants of all types, 
indicating that any DNA change can disrupt pre-mRNA processing. We demonstrate 
that a wide range of regulatory elements can be involved, including the canonical 
and cryptic splice sites, the polypyrimidine tract and splicing enhancers/silencers. 
Twenty mutations were predicted to truncate the BRCA proteins and/or to delete 
essential domains, thus supporting a role in HBOC.  
Conclusions: An important fraction of DNA variants of BRCA1/2 presents splicing 
aberrations that may represent a relevant disease-causing mechanism in HBOC. The 
identification of splicing disruptions by functional assays is a valuable tool to 
discriminate between benign polymorphisms and pathogenic mutations. 
 
INTRODUCTION 
Inactivating mutations in BRCA1 (MIM 113705) and BRCA2 (MIM 600185) 
confer a high risk of developing breast (BC) and ovarian cancers (OC).[1,2] Both 
genes are responsible for approximately 16% of the familial breast cancer risk.[3] 
Genetic testing for BRCA1 and BRCA2 provides valuable information in determining 
the clinical management of breast/ovarian cancer patients. However, the data it 
provides is also difficult to interpret due to the identification of many DNA variants of 
unknown physiological significance, or unclassified variants (UVs) that hamper 
genetic counselling in Hereditary Breast/Ovarian Cancer (HBOC). The critical issue is 
to identify whether a given nucleotide change results in a benign polymorphism or a 
disease-causing mutation. In fact, approximately half of the 3,499 different sequence 
variations of the BIC database1 are UVs and determining their biological impact 
remains a challenge.[4,5] 
Analysis of the deleterious effect of genetic variants in disease genes is usually 
focused on the predicted effect on protein structure and function. However, precise 
removal of introns from precursor mRNA or splicing is an essential step in eukaryotic 
gene expression. In spite of the low conservation of the basic splicing signals 
(donor/acceptor sites) in upper eukaryotes, exon recognition can be accurately 
achieved by additional cis-Splicing Regulatory Elements (SRE) that promote 
(enhancers) or repress (silencers) exon inclusion.[6,7] The study of the connections 
between defective splicing and disease has become a central issue in Biomedicine as 
a consequence of the growing list of point mutations linked to aberrant splicing.[6-
10] Any DNA variant that disrupts such elements can be a potential deleterious 
mutation.[6] This feature is particularly interesting in synonymous mutations (no 
change in protein sequence) which have traditionally been considered innocuous 
polymorphisms. One of the first examples of mutations disrupting an SRE was the 
BRCA1 mutation c.5080G>T,[11,12] which was correlated with exon 18 skipping. 
Since then, numerous mutations affecting SREs have been reported in a wide range 
of inherited diseases, such as Cystic Fibrosis (MIM 219700), Neurofibromatosis Type 
I (MIM 162200) and hereditary cancer.[7,10,13] An unexpectedly large percentage 
of mutations play a key role in human disease through the alteration of the pre-
mRNA processing step. In fact, it has recently been proposed that up to 60% of 
mutations that cause genetic diseases alter the splicing process.[8,9]  
The numerous and diverse cis-acting splicing elements present in human 
genes, as well as the high density of mutations in BRCA1 and BRCA2 (~1 mutation/7  
nucleotides), make these genes excellent models to study the correlation between 
aberrant splicing and BOC. Our purpose was to reanalyze the BRCA genes from the 
splicing perspective. We thus examined the functional consequences on splicing of 24 
BRCA variants carried by our patients and another 33 putative splicing variants that 
we created by direct mutagenesis. They were assayed by RT-PCR of lymphocyte 
mRNA and/or hybrid minigene experiments in human cell lines. We detected 28 
variants that altered the splicing process by different mechanisms, suggesting that 
aberrant splicing of BRCA1/2 may represent an important ethiopathogenic 
mechanism in HBOC. 
                                                                                                                                                                                     
1 http://research.nhgri.nih.gov/projects/bic/Member/index.shtml 
MATERIALS AND METHODS 
Patients, Nucleic Acid Isolation and Mutation Detection. 
Breast/ovarian cancer patients of 688 unrelated families were selected in the 
Genetic Counselling Unit according to the criteria previously described.[14] Written, 
informed consent was obtained from all patients prior to blood extraction. 
DNA and RNA were purified from peripheral blood lymphocytes by using the 
QIAamp DNA and RNA blood mini kits (Qiagen, Hilden, Germany), respectively. 
Mutation analysis of BRCA1/2 was carried out by heteroduplex analysis on an 
ABI3130XL capillary DNA sequencer (Applied Biosystems, Foster City, CA).[15] 
Mutation nomenclature follows the guidelines of the Human Genome Variation 
Society2. 
Splicing Prediction Programs  
Mutant and normal sequences were analyzed with several bioinformatic tools 
to identify potential splicing mutations. Disruption/creation of splice sites was 
evaluated with NNSPLICE3.[16] Analysis of putative SREs was performed with two 
web-based resources: ESEfinder4, that detects exonic splicing enhancers (ESE) for 
the SR proteins SF2/ASF, SC35, SRp40 and SRp55;[17] and the ESRsearch tool5, that 
identifies enhancers/silencers.[18] Besides its own algorithms, ESRsearch integrates 
those of RESCUE-ESE6,[19] PESX7,[20] and detection of known regulatory motifs. To 
                                                          
2 (http://www.hgvs.org/mutnomen/). 3 http://www.fruitfly.org/seq_tools/splice.html 
 
4 http://exon.cshl.edu/ESE/index.html. 5 http://ast.bioinfo.tau.ail/ 
 
6 http://genes.mit.edu/burgelab/rescue-ese/. 7 http://cubweb.biology.columbia.edu/pesx/programs 
 
ascertain the evolutionary conservation of ESE motifs, human BRCA1 and BRCA2 
sequences were aligned with those of other organisms using CLUSTALW28.[21]  
RT-PCR 
Lymphocyte RNA was retrotranscribed with the SuperscriptIITM kit (Invitrogen, 
Carlsbad, CA). Amplification was conducted with Platinum Taq (Invitrogen) and 
flanking exonic primers (Supplemental Table S1). Twelve unrelated lymphocyte RNAs 
and normal breast RNA were used as controls. 
Construction of Minigenes 
Mutant and wild type (wt) exons of BRCA1/2 and flanking intronic sequences 
were amplified with PfuUltra High fidelity polymerase (Stratagene, La Jolla, CA) and 
primers containing a 5’-tail with a restriction site for XhoI, BamHI or BglII 
(Supplemental fig S1 and Table S2). After restriction enzyme digestion, fragments 
were cloned into the exon trapping vector pSPL3 (Invitrogen) to transform 
Escherichia coli DH5α cells. To confirm the fidelity of the cloned sequences, plasmids 
were sequenced with the Big Dye 3.1 Sequencing Kit (Applied Biosystems) and 
primers PSPL3-SEQ-FW (5’-CCTTGGGATGTTGATGAT-3’) and PSPL3-SEQ-RV (5’-
TTGCTTCCTTCCACACAG-3’). Minigenes were transfected into HeLa and non-
tumorigenic breast epithelial cells (MCF10A) [22] (ATCC, LGC Standards, Spain) with 
Lipofectamine (Invitrogen). RNA was purified with Nucleospin-RNA-II (Macherey-
Nagel, Düren, Germany) and RT-PCR performed as indicated above. Normal and 
anomalous bands in agarose gels were quantified with the Quantity One software 
v4.5.2 (BioRad, Hercules, CA) and sequenced.  
Site directed mutagenesis 
                                                          
8 http://www.ebi.ac.uk/Tools/clustalw2/index.html 
Direct Mutagenesis was carried out according to the PCR mutagenesis 
protocol9 with PfuUltra polymerase. Previously constructed minigenes of exons 5-6-7, 
13 and 14 of BRCA1 and 3, 5-6-7 and 18 of BRCA2 were used as templates to 
generate 31 mutations from the BIC database (Supplemental Data). Experiments 
were performed by triplicate and densitometric results of exon inclusion/exclusion 
bands between wild type and mutant minigenes and between HeLa and MCF10A 
cells were compared with a t-test.  
                                                          
9 http://www.methodbook.net/PCR/PCRmut.html 
RESULTS 
A total of 167 DNA variants were detected in 688 BOC unrelated patients, 49 
of which (103 unrelated families) were classified as deleterious. All the variants were 
analyzed with NNSPLICE (splice sites) and ESEfinder and ESRsearch 
(enhancers/silencers). Twenty-four mutations were selected because they affected 
presumed SRE motifs or created/disrupted splice sites (Table 1; Supplemental Table 
S3).  
Analysis of putative splicing variants of our breast/ovarian cancer families 
Splice site mutations 
Six variants affected the natural splice sites (Table 1), BRCA1 c.211A>G, 
c.212+1G>A, c.5153-1G>A, c.5277+1G>A, and BRCA2 c.68-7T>A and c.7007G>A, 
and one created a cryptic donor site, BRCA2 c.1763A>G. These variants were tested 
by lymphocyte RT-PCR and/or hybrid minigenes, except for c.5277+1G>A, since 
patient RNA or DNA were not available.[23] All of them induced aberrant splicing of 
their exons (fig 1A, Table 1).[24-26] Apart from the classical mutations of the donor 
and acceptor splice sites, two variants should be highlighted. Firstly, the novel BRCA2 
missense variant c.1763A>G (p.N588S, exon 10) affected a non-conserved residue of 
the BRCA2 protein10 and could be considered neutral a priori. However, this DNA 
change was predicted to create a strong cryptic donor site, which led to an 
alternative transcript with an in-frame deletion of 147 nucleotides (fig 1) (predicted 
effect: p.N588S and loss of 49 amino acids). Secondly, c.68-7T>A affected the 
polypyrimidine tract of the acceptor site of BRCA2 intron 2. Minigene analysis 
                                                          
10 http://agvgd.iarc.fr/BRCA2_Align.htm 
revealed partial exon 3 skipping (Supplemental fig S2) that had also been reported in 
fibroblasts.[27]  
SRE mutations 
We also evaluated seventeen variants that disrupted putative SREs according 
to ESEfinder and ESRsearch (Table 1, Supplemental Table S3). Five of them (29.4%) 
showed different types of splicing alterations in RT-PCR analysis. The new BRCA1 
variants c.4379G>A (silencer creation) and c.4392T>A (enhancer disruption), 
appeared together in two unrelated patients. Lymphocyte RT-PCR revealed two 
aberrant products that corresponded to skipping of exon 15 and exons 14+15 (fig 
1B). BRCA1 c.5123C>A showed partial in-frame skipping of exon 18 (fig 1B,C) in 
lymphocytes. This mutation eliminated one SC35 and one conserved SRp55 
enhancers (ESEfinder) and generated one ESS (ESRsearch). RT-PCR analysis of the 
new BRCA2 mutation c.439C>T (p.Q147X) showed significant exon 5 removal (fig 
1B). It was suggested that this mutation disrupted one SRp40 motif and created two 
silencers. The synonymous mutation c.9234C>T disrupted one SRp40 motif, 
although it also created ESSs. Lymphocyte RT-PCR showed partial exon 24 skipping 
(data not shown). Finally, the nonsense mutation c.145G>T, which disrupted one 
conserved SF2/ASF motif, induced exon 3 skipping in minigene assays (fig 2A).  
The remaining 12 variants did not show any remarkable splicing consequence 
(Supplemental Table S3). The feature common to most negative SRE variants was 
the absence of evolutionary conservation of the disrupted elements. In fact, several 
of these variants had previously been suggested as non-deleterious DNA changes, 
such as BRCA1 c.4535G>T, and BRCA2 c.125A>C, c.223G>C, c.1114C>A, 
c.7397C>T and c.8182G>T.[4,5,28] Despite BRCA2 c.7994A>G and c.9375C>G 
disrupted conserved ESEs, they did not affect splicing probably because they are 
present in exons with strong splice sites which are supposed to be less dependent on 
SREs.[29] 
To summarize, 31 unrelated patients carried twelve different splicing variants, 
seven of which affected splice sites (BRCA1-c.211A>G, c.212+1G>A and c.5153-
1G>A and c.5277+1G>A and BRCA2-c.68-7T>A, c.1763A>G and c.7007G>A) and 
five altered SREs (BRCA1-c.4379G>A+c.4392T>A and c.5123C>A, and BRCA2-
c.145G>T, c.439C>T and c.9234C>T).  
With regard to the protein effect (Table 1; Supplemental Table S4), three 
variants were predicted to truncate the BRCA proteins, one variant (BRCA2-
c.145G>T) caused an in-frame deletion of the essential PALB2 binding domain of 
BRCA2, four BRCA1 variants had a double effect, protein truncation and in-frame 
deletion of critical protein domains (Ring Finger, SQ-cluster and BRCT domains of 
BRCA1). Evaluation of co-occurrence and family history [4] of eight variants supports 
their pathogenicity in six of them (probability of causality>0.99; Supplemental Table 
S4). Moreover, another two mutations (BRCA1 c.5123C>A and c.5277+1G>A) were 
previously predicted to be deleterious with odds in favour of causality >1011.[4] 
Furthermore, the previously reported founder effects of BRCA1 splicing mutations 
c.211A>G and c.5153-1G>A also support their pathogenic relevance.[24,30] On the 
other hand, splicing variants BRCA1 c.4379G>A+c.4392T>A and BRCA2 c.1763A>G 
reached P-values of 0.922 and 0.724, respectively. BRCA2 c.1763A>G was predicted 
to cause an in-frame deletion of 49 amino acids of unknown importance  since it 
does not affect any recognized functional domain. Finally, three variants were 
correlated with partial splicing outcomes with different interpretations. Only BRCA1 
c.5123C>A (p.A1708E) was previously catalogued as deleterious by protein 
functional assays and statistical evaluations.[4,31] Thus, it is plausible that the 
pathogenicity of this variant may rely on both protein and splicing anomalies. 
Splicing analysis of BIC and artificial mutations 
To further evaluate the incidence of defective splicing in BRCA1/2, we 
analyzed mutations from the BIC database. For this purpose, we included BIC 
mutations from exons 5-6-7, 13 and 14 of BRCA1 and 3, 5-6-7 and 18 of BRCA2, 
which were evaluated for splice site disruption or creation (NNSPLICE), disruption of 
conserved ESEs and ESS creation (ESEfinder and ESRsearch). Thirty-one putative 
splicing mutations were selected that comprised 28 nucleotide substitutions (22 
missense, 3 nonsense, 1 synonymous, 2 IVS), one intronic deletion and, as 
examples, two frameshift deletions. Another two artificial variants (BRCA1 c.165G>A 
and BRCA2 c.439C>A) were designed with ESEfinder and ESRsearch to target 
specific SREs. All of them were generated by site-directed mutagenesis taking 
advantage of previous wt minigene plasmids. 
Splicing functional assays showed that 16 variants (48.5%) caused different 
degrees and types of aberrant splicing (P<0.05, 5 variants; P<0.005, 10 variants; 
and P=0.13 for BRCA2-c.518G>T) (Table 2; figs. 2B-3; Supplemental figs. S2-S3). 
Three variants affected the natural splice sites (BRCA1-c.212+3A>G, c.302-3C>G, 
BRCA2-c.8331G>A), five created cryptic sites (BRCA2-c.467A>G, c.518G>T, 
c.7988A>T, c.8035G>T and c.8168A>G), one disrupted the polypyrimidine tract 
(BRCA2-c.426-12del5), and seven affected ESE/ESS (BRCA1-c.165G>A, c.178C>T, 
BRCA2-c.93G>T, c.439C>A, c.455C>A, c.470del5 and c.473C>T). These mutations 
had been reported 54 times in the BIC database. Most induced important or total 
aberrant splicing of their exons (12/16), but four (BRCA2-c.455C>A, c.518G>T, 
c.7988A>T, c.8168A>G) caused a partial effect (fig 2B, Supplemental figs. S2-S3).  
BRCA1 c.211A>G, c.212+1G>A and c.212+3A>G caused a similar splicing 
defect in minigene experiments (Tables 1 and 2, fig 3): exon 5 skipping and loss of 
22 nucleotides due to the use of a cryptic donor site. In contrast, other exon 5 
variants, such as c.165G>A and c.178C>T, just induced exon skipping.  
Interestingly, the amino acid change p.W31C (BRCA2-c.93G>T) was 
previously established to disrupt the DNA repair function of BRCA2.[32] However, we 
have found that c.93G>T induced exon 3 skipping and thus the Cys31 codon will not 
be present in the mature mRNA (Supplemental fig S2).  
Four out of six variants of BRCA2 exon 5 displayed aberrant splicing. BIC 
mutations at codon 147 (c.440A>G and c.441A>T) did not affect exon 5 splicing as 
c.439C>T, despite the fact that they disrupted the same SRp40 motif (fig 2B). 
However, neither variant created a silencer as with c.439C>T (ESRsearch). We then 
designed mutation c.439C>A (SRp40 disruption and creation of three ESSs, Table 2) 
that also induced exon 5 skipping (fig 2B).  
Four out of nine variants caused abnormal splicing of BRCA2 exon 18 
(Supplemental Fig. S3). Three of them created cryptic splice sites, causing a deletion 
of 298 nucleotides (c.8035G>T) and partial loss of 164 (c.8168A>G), whereas 
c.7988A>T induced partial exon skipping (reported in [33]), but also a deletion of 
345 nucleotides. Finally, c.8331G>A affected the donor site and provoked total exon 
18 skipping. None of the five missense mutations directed to conserved ESE 
significantly altered splicing, although variant c.8165C>G [34] showed a weak exon 
18 skipping in minigene context, also detected by other authors.[33,35]  
Six positive splicing mutations showed simultaneous ESE disruption/ESS 
creation by bioinformatic analysis (BRCA1-c.178C>T, BRCA2-c.93G>T, c.439C>A, 
c.455C>A, c.470del5, c.473C>T). Only the synonymous mutation BRCA1 c.165G>A 
was an apparent strict ESE mutation (three motifs) that caused exon 5 skipping (fig 
3).  
Seven variants were predicted to truncate the BRCA proteins (Table 2, 
Supplemental Table 4), three variants were suggested to cause in-frame deletions of 
essential domains (Ring Finger of BRCA1 and PALB2 binding domain of BRCA2), two 
variants were predicted to produce both effects, and one missense change 
(p.D2723G) with a partial splicing outcome was previously demonstrated to 
inactivate BRCA2.[33] Moreover, four variants (BRCA1-c.212+3A>G, c.302-3C>G, 
BRCA2-c.7988A>T and c.8168A>G) were previously estimated with odds in favour of 
causality of at least 120:1. Altogether these observations support the pathogenicity 
of 13 of these splicing variants. The disease causality of the remaining three variants 
was uncertain since one of them (c.467A>G) deleted three non-conserved residues 
of BRCA2 and two were non-conserved missense variants (BRCA2-c.455C>A and 
c.518G>T) that caused partial splicing outcomes. 
Regulation of alternative splicing is tissue-specific and it is well known that 
tumor cells show global aberrant splicing patterns.[36] We proceeded to confirm all 
the results in non-tumor cells from the target tissue of the disease. The positive 
mutant minigenes were transfected into non-tumor breast cells (MCF10A). All 
anomalous events were corroborated, albeit some quantitative differences between 
both types of cells were observed (fig 3). For example, mutations c.165G>A, 
c.178C>T, and c.212+1G>A of BRCA1 exon 5 led to almost total exon 5 skipping in 
MCF10A, whereas this effect was apparently less pronounced in HeLa. However, the 
differences in band intensities were not statistically significant (Fig. 3). 
DISCUSSION 
A high proportion of BRCA1/2 variants reported in the BIC database have not 
been classified as either deleterious or neutral. In this work, we have developed a 
powerful combined strategy to study the potential effect of genetic variants on 
splicing efficiency: Bioinformatic analysis followed by functional analysis (average 
successful rate of 49.1%). Predictions of the splicing software can be considered 
useful, but only complementary, tools for identifying candidate splicing mutations 
since they must necessarily be confirmed by a functional assay. ESEfinder and 
ESRsearch were not so precise, since they systematically recognize all the motifs that 
can act as putative regulators. Their sensitivity can be increased by filtering the 
output data with other parameters such as strict evolutionary conservation of the 
ESE motif, strength and proximity of the splice sites.[7,37,38]  
Splicing Functional Assays 
We found that 28/57 variants exhibited different degrees and types of 
aberrant splicing (Tables 1-2). The minigene assay has been shown to be a 
straightforward and reliable method for studying potential splicing mutations without 
the need of patient RNA.[39] Results of lymphocyte RT-PCR were reproduced in 
minigene experiments in variants tested by both methods,[24-26,33,40-44] except 
for quantitative differences of aberrant isoforms.  
All anomalous events of HeLa-minigenes were confirmed in breast epithelial 
cells-MCF10A (fig 3). These results allowed us to discard possible artefacts derived 
from the global alteration of splicing patterns in tumor cells that could have masked 
the real splicing consequence.[36] Given that non-tumor breast tissue samples from 
BRCA carriers are practically unavailable, the use of minigenes in MCF10A cells is an 
excellent approach for reproducing the splicing outcome in this tissue. Finally, the 
combination of minigene and PCR mutagenesis techniques allows the splicing 
analysis of any DNA variant reported worldwide, as well as mapping of key SREs. 
Disruption of splicing regulatory elements. 
A wide variety of splicing elements were involved: the natural splice sites (7 
mutations), the polypyrimidine tract (2 mutations), cryptic splice sites (7 mutations); 
and different exonic SRE motifs (12 mutations), illustrating the high complexity of 
exon recognition that depends on multiple parameters.[29] Moreover, an important 
fraction of variants affected exonic motifs (12 SREs and seven cryptic splice sites), a 
fact that supports the idea that any DNA change should be investigated in depth.  
According to ESEfinder and ESRsearch, many different SRE motifs were 
involved in aberrant splicing: SC35, SRp40, SRp55, SF2/ASF, hnRNPB and other SREs 
without a known binding protein. Most functional SREs were placed in close proximity 
to the splice sites, in keeping with the previously reported position effect of these 
elements.[38] Computational SRE search produced conflicting results (enhancer 
disruption/silencer creation) in 10 positive mutations, but the significance of these 
data can only be solved experimentally. For example, in silico analysis of BRCA1 
c.5080G>T predicted the disruption of one SF2/ASF enhancer, but it has recently 
been demonstrated that the mutant sequence specifically binds to the repressor 
factors hnRNPA1/A2 and DAZAP1.[11,12] We found that all the mutations at codon 
147 of BRCA2 disrupted the same SRp40 motif, but only two (c.439C>T and 
c.439C>A), which created silencers, caused exon 5 skipping, suggesting that the 
binding of repressors is the underlying molecular mechanism. These results also 
illustrate the fine balance between positive and negative determinants necessary for 
exon identity.[45] Alternatively, strict ESE mutations seemed to be BRCA1 c.165G>A 
and BRCA2 c.145G>T, which only disrupted conserved ESEs and were correlated 
with skipping of their respective exons (figs 2-3).  
The influence of the genomic context is another factor that regulates the 
splicing process.[7] A representative example is the “splicing interdependence” of the 
exon cluster 34-38 of the Neurofibromatosis type I gene, where a mutation of exon 
37 (6792C>G) causes skipping of exons 36+37 and exon 37. Our results suggest 
that variants c.4379G>A+c.4392T>A of BRCA1 exon 14 triggered skipping of exon 
15 and exons 14+15. The exact, underlying mechanism is unknown and should be 
confirmed with a minigene containing both exons. 
Reclassification of mutations  
Reclassification of UVs as deleterious under the splicing viewpoint may notably 
increase the proportion of HBOC families who may benefit from tailored prevention 
protocols. Thirteen missense, 3 nonsense, 4 synonymous, 1 frameshift and 7 intronic 
variants produced abnormal splicing patterns, indicating that any DNA change should 
be regarded as a potential splicing mutation. Of these, 20 (12 missense, 4 
synonymous, 4 IVS) were previously considered UVs or mere polymorphisms. 
Consequently, splicing should be considered a primary mechanism of pathogenicity 
to be investigated in UVs. Nevertheless, effects on protein function must not be 
disregarded, since several negative missense changes affected strongly conserved 
amino acids, supporting their functional importance. Actually, several missense 
changes were formerly demonstrated to inactivate BRCA1/2 at the protein 
level.[31,33] Another interesting example is missense c.5123C>A (p.A1708E), which 
inactivates BRCA1 through a double mechanism: alteration of the protein function 
(disruption of the BRCT domain),[31] and a decrease of the exon 18 splicing 
efficiency (fig 1) by the binding of specific repressors.[41] Also, BRCA2 c.8168A>G 
(p.D2723G) of exon 18 (DNA binding domain) was demonstrated to inactivate BRCA2 
at the protein level,[33] but we also found a splicing isoform with a deletion of 164 
nucleotides.  Intriguingly, the missense mutation p.W31C (c.93G>T) was reported to 
disrupt the interaction BRCA2-PALB2, which is essential for recombinational repair 
and checkpoint functions.[32] Conversely, our minigene experiment demonstrates 
that this mutation induces the almost complete in-frame skip of BRCA2 exon 3 by 
disruption of SREs (Table 2), thereby, this amino acid change will not be present in 
the majority of mutant proteins and BRCA2-PALB2 interaction would be impeded as 
well.  It would also be interesting to test p.W31R (c.91T>C), which also abolished 
PALB2-BRCA2 interaction,[32] but our bioinformatic analysis indicated no disruption 
of the ultraconserved SC35 motif of c.93G>T. Reclassification of missense and 
protein truncation mutations (e.g. BRCA2 c.439C>T or c.470del5) as splicing 
alterations might also have an impact in the penetrance and expressivity of such 
mutations. The reduced penetrance of BRCA1 c.211A>G lends further support to this 
hypothesis.[46]  
Genetic susceptibility to breast/ovarian cancer 
A high proportion (28/57, 49.1%) of assayed mutations disrupted pre-mRNA 
processing. This suggests that the prevalence of splicing mutations may have been 
vastly underestimated. If we make a short review of the BIC mutations of exons 5-6-
7, 13, 14 of BRCA1 and 3, 5-6-7, 18 of BRCA2, we find 26 variants of the AG/GT 
canonical splice sites which, together with our data of such exons, 4 BIC mutations 
of our patients (c.211A>G, c.5153C>A, c.68-7T>A and c.145G>T) and 14 positive 
engineered BIC mutations, account for 44 splicing variants. They therefore constitute 
22.1% of variants of those exons reported in the BIC database, which may be even 
higher, given that only two frameshift mutations (c.470_474delAGTCA and 
c.594_595delAT) were examined in our study. In comparison, the low-penetrance 
genes ATM, CHK2, PALB2 and BRIP1 scarcely make any contribution, with about 50 
mutations to BC susceptibility after analysis of a large number of families (Human 
Gene Mutation Database11), accounting for less than 2.3% of the familial risk of 
breast cancer.[3] Moreover, splicing is the major pathogenic mechanism of BRCA1 in 
our HBOC families (58.5% of BRCA1 families), although the mutations c.211A>G, 
c.212+1G>A, c.5153-1G>A and c.5123C>A are very frequent in our population (21 
families).[24,30] Furthermore, typical screening protocols only scan ~25 Kb out of 
the 160 Kb of the genomic sequences of BRCA1/2, so deep intronic mutations may 
be missed. For example, the GTAA deletion of intron 20 of the ATM gene promotes 
the exonization of a cryptic exon.[47] However, other authors have suggested a 
minor role for such mutations in the molecular spectrum of BRCA1/2. [48] 
One important question is to elucidate the carcinogenic power of mutations 
with incomplete splicing effects. Variants with strong effects (20 variants, 
Supplemental Table S4) are probably deleterious, since they inactivate BRCA1/2 
functions through protein truncation and/or deletion of essential protein domains. 
Moreover, 12 variants have been predicted to be deleterious by an integrated 
evaluation approach (Supplemental Table S4),[4] which provides additional support 
to our findings. Nevertheless, the involvement in BC susceptibility of weaker splicing 
variants, such as c.68-7T>A or c.518G>T of BRCA2 or missense changes with 
                                                          
11 http://www.hgmd.cf.ac.uk/ac/index.php 
incomplete effects on protein function, is more uncertain.[27] This question should 
be addressed by a more comprehensive study, including supplementary functional 
assays and epidemiological and statistical analyses.[4,49] Partial splicing mutations 
might contribute to the BOC genetic spectrum, providing low-moderate cancer 
susceptibility alleles that might act synergistically with other low penetrance alleles to 
increase the general risk of breast cancer. All these parameters should be integrated 
in a unique model of BOC risk, which would include susceptibility and protector 
alleles,[50] as well as environmental and lifestyle factors, with a view to providing 
individual risk assessment, which seems to be one of the most laborious 
undertakings.  
In conclusion, we have shown that defective splicing is an important 
inactivating mechanism of the BRCA genes. Our results also suggest that careful 
interpretation is needed for the pathological nature of DNA variants, particularly 
when changes in protein function cannot be evaluated. The implantation of simple, 
cost effective splicing assays in the genetic diagnostic laboratory may contribute to 
the classification of variants of unknown clinical significance. Finally, splicing analysis 
of human disease genes also contributes to the basic knowledge of the regulatory 
mechanisms of this process. 
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Figure 1. Analysis of putative splicing variants of the BRCA1 and BRCA2 genes by 
RT-PCR of lymphocyte RNA from patients with flanking exonic primers. A) Analysis of 
splice site variants. Products are visualized after ethidium bromide staining of 1.5-
2.0% agarose gels (inverted images). Boxes indicate exon composition. C, Control 
RNA; St, DNA standard: ladder 123 bp (Invitrogen). B) Analysis of enhancer/silencer 
variants. C) Evolutionary conservation of enhancers disrupted by mutation 
c.5123C>A of BRCA1 exon 18. Conserved SRp55 motif is boxed and non-conserved 
SC35 sequence is underlined in Homo sapiens.  
 
Figure 2. Splicing Functional Assays of hybrid minigenes of BRCA2. Boxes indicate 
exon structure: V1 and V2 are vector exons. A) Minigene constructions of BRCA2 
exons 3 (left) and 23 (right): mutations c.145G>T (lane 2) of exon 3 and mutation 
c.8997G>A (lane 5) of exon 23. Wild type minigenes of exons 3 and 23 are shown in 
lanes 1 and 4, respectively. Exon 3 skipping caused by mutation c.145G>T is 
indicated by an arrow whereas c.8997G>A had no effect on exon 23 splicing. B) 
Combined inverted images of agarose gel electrophoreses of RT-PCR of minigenes 5-
6-7 of BRCA2 carrying different mutations. Upper panel: 1, wt minigene; 2, c.426-
12del5; 3, c.439C>T; 4, c.455C>A; 5, wild type minigene + pSPL3; 6, c.473C>T; 7, 
c.439C>A; 8, double mutant c.455C>A+c.473C>T; 9, ladder 123 bp; 10, 
c.470_474del5; 11, wt minigene. Mutations of lanes 2, 4, 6, 7, 8, and 10 were 
created by site-directed mutagenesis. Lower panel: 12, c.455C>A; 13, c.467A>G; 14, 
ladder 123 bp. Exon skipping or abnormal splicing are indicated by arrows. RT-PCR 
product of c.467A>G slightly migrated below the normal band of the wt minigenes. 
Direct sequencing of this band revealed a 9 nucleotide-deletion (right). 
 
Figure 3. Reproducibility of splicing functional assays of BRCA1 minigenes in HeLa 
and MCF10A cells. Mutant and wild type minigenes of exons 5-6-7 were tranfected 
into HeLa cells (lanes 1-5) and MCF10A cells (lanes 7-11) and RT-PCR was carried 
out with exonic vector primers SD6-PSPL3_RTFW and SA2-PSPL3_RTREV. Boxes 
indicate exon structure: V1 and V2 are vector exons.An inverted image of a 1.5% 
agarose gel is shown. Lanes: 1, wt-Minigene; 2, c.165G>A; 3, c.178C>T; 4, 
c.212+1G>A; 5, c.212+3G>A. 6, ladder 123 bp; 7, wt-minigene; 8, c.165G>A; 9, 
c.178C>T; 10, c.212+1G>A; 11, c.212+3G>A. These experiments were performed 
at least in triplicate and HeLa/MCF10A densitometric values were compared with a t-
test: P=0.97 for c.178C>T (HeLa and MCF10A showed practically identical results), 
P=0.29 for c.178C>T, P=0.69 for c.212+1G>A, and P=0.36 for c.212+3G>A.  
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Bioinformatic study  
Splicing Regulatory Elements‡ mRNA Effect § Protein Effect|| Carriers 
Untested 
Relatives 
BRCA1       
c.211A>G (330A>G) / 
Mis 5 5 BC +3 bBC 8 BC, 1 Cx, 1 CRC 
Splice site disruption/Cryptic donor site 22 
nt upstream -[NNSPLICE] 
Ex 5del22 
Ex 5 skipping [Ly-RT/MG] 
PT (p.Cys64X) + 
IFD (p.Phe46_Arg71del)-Ring Finger  
c.212+1G>A 
(331+1G>A) /IVS 3 2 BC+3 OC 
3 BC, 2 OC, 1 Bla, 1 
End, 1 CRC 
 Splice site disruption/ 
Cryptic donor site-[NNSPLICE] 
Ex 5del22 
Ex 5 skipping [Ly-RT/MG] 
PT (p.Cys64X) + 
IFD (p.Phe46_Arg71del)-Ring Finger 
c.4379G>A /Mis +  
c.4392T>A /Syn 2 2 BC 2 BC 
ESS creation-[PESX] 
ESE disruption/SRp40,SC35-[ESEfinder]  
Ex 15 skipping 
Ex 14-15 skipping [Ly-RT] || 
PT (p.Ser1496GlyfsX13) + 
IFD (p.Ala1453_Leu1588del) –SCD 
c.5123C>A 
(5242C>A) /Mis 6 3 bBC, 4 BC 
14 BC, 1 OC , 2 GC, 
1 End, 1 CRC 
ESE disruption/SC35,SRp55-[ESEfinder] 
ESS creation-[PESX/ESRsearch] 
Partial exon 18 skipping  
[Ly-RT] 
IFD (p.Asp1692Gly, Ala1693_Trp1718del)-
BRCT + p.A1708E  (P. F.) 
c.5153-1G>A 
(5272-1G>A) / IVS 7 
10 BC, 2 bBC, 2 
OC + 1 CRC 
10 BC, 4 OC, 4 GC, 
10 others 
Splice site / Cryptic acceptor site 1nt 
downstream -[NNSPLICE] 1 nt deletion [Ly-RT] PT (p.Val1719X) 
c.5277+1G>A  
(5396+1G>A) / IVS 1 1 BC (5 OC) [23] 1 BC  Splice site disruption-[NNSPLICE] 
Retention 87 nt Intron 20, 
Ex 20 skipping  
IFD (p.His1732_Lys1759del)-BRCT + PT 
(p.Lys1759_Ile1760ins29) 
BRCA2       
c.68-7T>A (296-
7T>A) / IVS 2 2 BC 
5 BC, 1 GC, 1 
leukemia Polypyrimidine tract-[NNSPLICE] Partial ex 3 Skipping [MG] IFD (p.Asp23_Leu105del)-PBD + wt 
c.145G>T (373G>T) 
/Non 1 2 BC 3 BC, 1 OC 
ESE disruption/SF2/ASF-
[ESEfinder/PESR] Ex 3 Skipping [MG] IFD (p.Asp23_Leu105del)-PBD 
c.439C>T (667C>T) 
/Non 1 1 BC 2 BC, 1 bBC, 2 OC 
ESE disruption/SRp40-[ESEfinder]  
ESS creation-[PESX] Ex 5 skipping [Ly-RT/MG] PT (p.Pro143GlyfsX22) 
c.1763A>G 
(1991A>G) /Mis 1 1 bBC  
Cryptic donor site 147 nt upstream-
[NNSPLICE] Del 147 nt-ex10 [Ly-RT] IFD (p.Asn588_Gly637del, p.N588S) 
c.7007G>A 
(7235G>A) /Mis 1 3 BC   Splice site disruption-[NNSPLICE] Ex13 Skipping [Ly-RT] PT (p.Gly2313AlafsX40) 
c.9234C>T 
(9462C>T) /Syn 1 1 BC  
ESE disruption/SRp40-[ESEfinder/PESR] 
ESS creation-[Rescue-ESE/PESX ] 
Partial ex24 skipping 
[Ly-RT] PT (p.Val3040AspfsX18)+ wt 
* Mutations described at the BIC database are shown in bold. The rest of the mutations were described by our group[14]. Descriptions of mutations follow the nomenclature guidelines of the Human Genome Variation Society 
(www.hgvs.org). BIC nomenclature is shown between parentheses. Types of mutations are indicated: Syn, Synonymous; Non, Nonsense; IVS, Intronic Variant; Mis, Missense. 
† BC, breast cancer; bBC: bilateral breast cancer; Bla, bladder cancer; Cx, cervix cancer, CRC, colorectal cancer; GC, gastric cancer; OC, ovarian cancer. Mutation c.7007G>A has been found in another family with bilateral 
breast cancer and male breast cancer.[25] 
‡ ESE: Exonic Splicing Enhancer; ESS: Exonic Splicing Silencer; nt, nucleotide. Splicing prediction programs are shown between brackets: NNSPLICE, PESR, Rescue-ESE, PESX, PESR and ESRsearch. Full data of 
bioinformatic study are available upon request.  
§ Method between brackets: Ly-RT, Lymphocyte RT-PCR; MG, Minigene assay; Ex; Exon; Del, deletion.. Effects of mutations c.211A>G, c.5153-1G>A, c.5277+1G>A and  c.7007G>A on lymphocyte RNA have also been 
reported [23-26].  
|| Mutation designations (protein level) according to the Human Genome Variation Society (www.hgvs.org) are between parentheses. Protein Effect: PT, Protein Truncation; IFD, In-frame deletion; BRCT, BRCA1 C-
Terminal Domains (amino acids 1,646-1,859); PBD, PALB2 Binding Domain; SCD, SQ-cluster domains (amino acids 1,280-1,524) that are preferred sites of ATM phosphorylation.  
Table 2. BIC and artificial mutations engineered by site-directed mutagenesis that showed aberrant splicing in minigene assays. 
 
DNA variant  




Splicing Regulatory Elements † mRNA Effect§ Protein Effect§ 
BRCA1      
c.165G>A (284G>A) /Syn 5 - ESE disruptions/2 SRp40, SF2-[ESEfinder] Ex5 skipping IFD (p.Phe46_Arg71del)-Ring Finger 
c.178C>T (297C>T) /Non 5 4 
ESE disruptions/2 SF2, SRp55 -[ESEfinder]
ESS creation-[Rescue-ESE] Ex5 skipping IFD (p.Phe46_Arg71del)-Ring Finger 
c.212+3A>G (331+3A>G) /IVS I-5 13 Donor site disruption-[NNSPLICE] 
Ex5del22 + 
ex 5 skipping 
PT (p.Cys64X) +  
IFD (p.Phe46_Arg71del)-Ring Finger 
c.302-3C>G (421-3C>G) /IVS I-6 3 Cryptic acceptor site-[NNSPLICE] 2 nt insertion ex7 PT (p.Ser72GlyfsX17) 
BRCA2      
c.93G>T (321G>T) /Mis 3 1 
ESE disruption/SC35 -[ESEfinder/PESR] 
ESS creation-[ESRsearch] Ex3 skipping IFD (p.Asp23_Leu105del)-PBD 
c.426-12del5 (654-12del5) /IVS I-4 1 Polypyrimidine tract-[NNSPLICE] Ex5 skipping PT (p.Pro143GlyfsX22) 
c.439C>A (667C>A) /Mis 5 - 
ESE disruption/SRp40 -[ESEfinder] 
3 ESS creation-[PESX] Ex5 skipping PT (p.Pro143GlyfsX22) 
c.455C>A (683C>A) /Mis 5 1 
ESE disruption/SRp40 -[ESEfinder] 
ESS creation-[PESX] Partial ex5 skipping PT (p.Pro143GlyfsX22) + p.T152K 
c.467A>G (695A>G) /Mis 5 8 Cryptic donor 9 nt upstream-[NNSPLICE] 9 nt del ex5 IFD (p.Asp156_Ser158del) (N.C.) 
c.470_474del5 (698del5) /Fr 5 1 
ESE disruptions/SF2,SC35,SRp55 -[ESEfinder] 
ESS creation-[Rescue-ESE] Ex5 skipping PT (p.Pro143GlyfsX22) 
c.473C>T (701C>T) /Mis 5 4 
ESE disruptions/SF2,SRp55 -[ESEfinder] 
5 ESS creation-[Rescue-ESE] Ex5 skipping PT (p.Pro143GlyfsX22) 
c.518G>T (746G>T) /Mis 7 1 Cryptic donor site -[NNSPLICE] Partial ex7 skipping PT (p.Gly174SerfsX19)+ p.G173V (N.C.) 
c.7988A>T (8216A>T) /Mis 18 9  Cryptic donor site-[NNSPLICE] 
Partial loss of 345 nt 
+Partial ex18 skipping  
IFD (p.Glu2663_Lys2777del) +  
PT (p.Tyr2664PhefsX43)+p.E2663V-DBD 
c.8035G>T (8263G>T) /Mis 18 1  Cryptic donor site-[NNSPLICE] Loss of 298 nt PT (p.Asp2679PhefsX43)-DBD 
c.8168A>G (8396A>G) /Mis 18 6  Cryptic donor site-[NNSPLICE] Partial loss of 164 nt PT (p.Gly2724PhefsX3)+p.D2723G (DBD-P. F.) 
c.8331G>A (8559G>A) /Syn 18 - Splice site disruption-[NNSPLICE] Exon 18 skipping PT (p.Tyr2664PhefsX43) 
* Artificial mutations 284G>A and 667C>A are italicized whereas BIC mutations are shown in bold. BIC nomenclature of mutations is shown between parentheses. Types of mutations are 
indicated: Syn, Synonymous; Non, Nonsense; IVS, Intronic Variant; Mis, Missense; Fr, Frameshift. DNA change c.8331G>A (8559G>A) of the BIC database is incorrectly assigned to codon 2776 
(p.K2777K). 
† ESE: Exonic Splicing Enhancer; ESS: Exonic Splicing Silencer. Splicing prediction programs are shown between brackets: PESR, Rescue-ESE, PESX and ESEfinder. Full data of bioinformatic 
study are available upon request. Evolutionarily conserved binding motifs of SR proteins are underlined. 
‡ Ex, exon; del, deletion; nt, nucleotide 
§ Mutation designations (protein level) according to the Human Genome Variation Society (www.hgvs.org) are between parentheses. Protein Effect: PT, Protein Truncation; IFD, In-frame 
deletion; PBD, PALB2 Binding Domain; DBD, DNA Binding Domain; N.C., Not conserved; P.F., Missense changes that affect the protein function. 
 
